


## Auglurant

<b>Cat. No.:</b>	HY-16617		
<b>CAS No.:</b>	1396337-04-4		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>12</sub> FN <sub>5</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	325.3		
<b>Target:</b>	mGluR		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 22.73 mg/mL (69.87 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		3.0741 mL	15.3706 mL	30.7411 mL
		5 mM		0.6148 mL	3.0741 mL	6.1482 mL
10 mM			0.3074 mL	1.5371 mL	3.0741 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Auglurant (VU0424238) is a novel and selective mGlu5 antagonist with an IC <sub>50</sub> value of 11 nM (rat) and an IC <sub>50</sub> value of 14 nM (human). Auglurant (VU0424238) has an acceptable CNS penetration <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	rat mGluR5 11 nM (IC <sub>50</sub> )	human mGluR5 14 nM (IC <sub>50</sub> )
<b>In Vitro</b>	Auglurant (VU0424238) with an IC <sub>50</sub> value of 14 nM in HEK293A cells. It also binding a known allosteric site with K <sub>i</sub> value of 4.4 nM in HEK293A cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Auglurant (VU0424238) had a clearance of 19.3 mL/min/kg in rats and demonstrates 50% mGlu5 PET ligand occupancy at an oral dose of 0.8 mg/kg in rats. Plus, it also had a clearance of 15.5 mL/min/kg in cynomolgus monkeys and demonstrates	

---

50% mGlu5 PET ligand occupancy at an oral dose of 0.06 mg/kg in baboons<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Felts AS, et al. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. J Med Chem. 2017 Jun 22;60(12):5072-5085.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA